IP Library Granted Patent US 9,333,340
Granted Patent B2
US 9,333,340 · App. 13/681,581 · Granted May 10, 2016

Methods and systems for glucose regulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,333,340
App. No.
13/681,581
Granted
May 10, 2016
Kind
B2
Abstract

Various methods and apparatus for treating a condition associated with impaired glucose regulation in a subject comprising in one embodiment, applying a neural conduction block to a target nerve at a blocking site with the neural conduction block selected to at least partially block nerve pulses. In another embodiment, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to treat impaired glucose regulation. In other embodiments, up-regulation or down-regulation of various nerves, such as the vagus and its branches, and the splanchnic is used to modify the production of GLP-1 and GIP, thereby controlling glucose levels. In yet further embodiments, combinations of down-regulating and or up-regulating with or without pharmaceutical agents are used to modify the production of GLP-1 and GIP, to treat impaired glucose regulation.

Claims (13)

1. A method of modifying the amount of GLP1, comprising:

applying a first intermittent electrical signal to an electrode positioned on a vagus nerve with said electrical signal selected to down-regulate afferent and efferent neural activity on the vagus nerve and to restore neural activity on the nerve upon discontinuance of said signal, and has a frequency of 500 Hz to 5000 Hz, wherein the first electrical signal is applied intermittently in a cycle including an on time of application of the signal followed by an off time during which the signal is not applied to the nerve, wherein the on and off times are applied multiple times per day over multiple days; wherein the on time is selected to have a duration of about 30 seconds to about 5 minutes; and wherein the electrical signal is selected to increase the amount of GLP1.

2. The method according to claim 1 , wherein the electrical signal is applied on the hepatic branch of the vagus nerve.

3. The method according to claim 1 , wherein the electrical signal is applied on the celiac branch of the vagus nerve.

4. The method according to claim 1 , further comprising applying a second electrical signal to a second target nerve or organ, wherein the second electrical signal is selected for frequency, pulse width, amplitude and timing to upregulate or down-regulate neural activity.

5. The method of claim 4 , wherein the downregulating and upregulating signals are applied at the same time or different times.

6. The method of claim 4 , wherein the second target nerve is the splanchnic nerve or the celiac branch of the vagus nerve.

7. The method of claim 4 , wherein the second target organ is the duodenum or ileum.

8. The method of claim 1 , further comprising detecting the level of GLP1 to determine whether to apply an electrical signal treatment.

9. The method according to claim 1 , further comprising administering an agent that improves glucose control.

10. The method of claim 9 , wherein the agent increases the amount of insulin and/or increases the sensitivity of cells to insulin.

11. The method of claim 10 , wherein the agent that increases the amount of insulin is selected from the group consisting of insulin, insulin analogs, sulfonylureas, meglitinides, GLP-1 analogs, and DPP4 inhibitors.

12. The method of claim 10 , wherein the agent that increases the sensitivity of cells to insulin is a PPAR alpha, gamma, or delta agonist.

Assignments (4)
SECURITY INTEREST Recorded Oct 24, 2024
From: RESHAPE LIFESCIENCES INC.
To: ASCENT PARTNERS FUND LLC
Reel/Frame 070166/0882 →
SECURITY INTEREST Recorded Jun 19, 2020
From: RESHAPE LIFESCIENCES INC.; RESHAPE MEDICAL LLC
To: ARMISTICE CAPITAL MASTER FUND LTD.
Reel/Frame 052987/0463 →
CHANGE OF NAME Recorded Mar 30, 2018
From: ENTEROMEDICS INC.
To: RESHAPE LIFESCIENCES INC.
Reel/Frame 045949/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2013
From: TWEDEN, KATHERINE S.; KNUDSON, MARK B.; WILSON, RICHARD R.; THORNTON, ARNOLD W.; KIM, DENNIS DONG-WON
To: ENTEROMEDICS, INC.
Reel/Frame 030048/0330 →